Alpdogan Onder, Grosso Dolores, Flomenberg Neal
Department of Medical Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Discov Med. 2013 Oct;16(88):159-65.
In the last two decades, new developments in haploidentical hematopoietic stem cell transplantation have made it a viable alternative donor option. Initially, allogeneic HSCT was limited to patients who had HLA-identical related donors. To provide options for patients lacking a matched related donor, registries of unrelated volunteer donors or cord blood units have been established with the hopes of providing a phenotypically well-matched stem cell product. The use of haploidentical donors broadens the application of HSCT more than these other approaches. In addition, the greater HLA mismatching associated with haploidentical HSCT may potentiate graft versus tumor (GVT) effects.
在过去二十年中，单倍体相合造血干细胞移植的新进展使其成为一种可行的替代供体选择。最初，异基因造血干细胞移植仅限于有 HLA 相合的相关供体的患者。为了给缺乏匹配相关供体的患者提供选择，已经建立了无关志愿供体或脐血库登记处，希望能提供表型匹配良好的干细胞产品。与其他方法相比，单倍体相合供体的使用更广泛地拓展了造血干细胞移植的应用。此外，与单倍体相合造血干细胞移植相关的更大程度的 HLA 不匹配可能会增强移植物抗肿瘤（GVT）效应。
